NCT07324629

Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma

A Phase II Clinical Study of Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma With Treatment Failure After Platinum-Based Therapy

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT. The main questions it aims to answer are: * How effective is drug Sac-TMT in treating Thymic Carcinoma? * What adverse events (AEs) do participants have when taking drug Sac-TMT? Participants will: * Progress after at least one platinum-based chemotherapy treatment. * Take drug Sac-TMT every 2 weeks. * Take tumor response assessments every 6 weeks.

Conditions

• Thymic Carcinoma

Interventions

Type	Name	Description
DRUG	Sacituzumab tirumotecan	Sacituzumab tirumotecan (Sac-TMT; also known as SKB264) for injection.

Timeline

• Start date: 2026-01-01
• Primary completion: 2028-04-01
• Completion: 2028-10-01
• First posted: 2026-01-07
• Last updated: 2026-01-09

Locations

1 site across 1 country: China